Result:Good· Market: Down#Base effect
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 88.62 | 5.4% | 34.5% |
| Total Income | 89.05 | 6.2% | 33.7% |
| Expenditure | 87.92 | 9.1% | 32.4% |
| PBT | 1.14 | 64.6% | 445.7% |
| Net Profit | 1.14 | 68.4% | 445.7% |
| OPM | 8.97% | 3.60pp | 0.23pp |
| NPM | 1.28% | 3.02pp | 0.97pp |
| EPS | 0.71 | 68.6% | 446.1% |
Revenue grew a healthy 34.5% YoY for a pharma name, but the 445% PAT jump is off a near-breakeven base (₹0.21cr) with OPM flat-to-down (9.2%→9.0%), so it's solid but not a true margin-driven standout.
Informational and educational content only. Not investment advice.